SCHEMBL4336024

SCHEMBL4336024

O=C(O)CC[C@H](NC(=O)N[C@H](CCCCNCc1ccccc1)C(=O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 18/20 1.00
▸ NAALAD2 Q9Y3Q0 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11977600 1.00 FOLH1 (1.00) FOLH1NAALAD2
SCHEMBL11977622 1.00 FOLH1 (1.00) FOLH1NAALAD2
SCHEMBL4673746 1.00 FOLH1 (1.00) FOLH1NAALAD2
SCHEMBL20312207 1.00 FOLH1 (1.00) FOLH1NAALAD2
SCHEMBL11977637 0.94 FOLH1 (0.89) FOLH1NAALAD2
SCHEMBL11984408 0.92 FOLH1 (0.84) FOLH1NAALAD2
SCHEMBL13554633 0.91 FOLH1 (0.83) FOLH1NAALAD2
SCHEMBL11977619 0.91 FOLH1 (0.83) FOLH1NAALAD2
SCHEMBL24336825 0.89 FOLH1 (1.00) FOLH1
SCHEMBL17700969 0.89 FOLH1 (1.00) FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 — — US claimed
EP-2097111-A2 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2009-09-09 — — EP claimed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 — — US claimed
WO-2008058192-A2 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-05-15 — — WO claimed
US-12534429-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2026-01-27 — — US disclosed
US-20230095637-A1 Heterodimers of Glutamic Acid CITIZENS BANK, N.A. 2023-03-30 — — US disclosed
EP-4023624-A1 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2022-07-06 — — EP disclosed
EP-3699162-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2022-06-29 — — EP disclosed
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID CITIZENS BANK, N.A. 2021-08-12 — — US disclosed
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 — — US disclosed
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 — — US disclosed
EP-3335736-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2020-12-30 — — EP disclosed
EP-2942065-A1 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2015-11-11 — — EP disclosed
EP-2097111-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2015-07-15 — — EP disclosed
US-8487129-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2013-07-16 — — US disclosed
US-20120269726-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2012-10-25 — — US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 — — US disclosed
EP-2097111-A2 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2009-09-09 — — EP disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 — — US disclosed
WO-2008058192-A2 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885
US-12534429-B2 Heterodimers of glutamic acid FOLH1, GLUL, SLC25A13 FOLH1 1/4885NAALAD2 15/4885
US-20120269726-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885
US-20230095637-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 9/4885
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback